EAM
CLDX icon

Exome Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Exome Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-73,000
Closed -$1.49M – 77
2025
Q2 		$1.49M Buy
+73,000
New +$1.42M 1.1% 42
2024
Q2 		– Sell
-71,100
Closed -$2.98M – 57
2024
Q1 		$2.98M Sell
71,100
-40,200
-36% -$1.65M 2.56% 11
2023
Q4 		$4.41M Buy
+111,300
New +$3.27M 4.36% 5

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Exome Asset Management's CLDX Position: Q3 2025 in Review

Exome Asset Management sold out of Celldex Therapeutics (CLDX) in Q3 2025, closing a stake of 73,000 shares — an estimated $1.49M sold.

Exome Asset Management first reported a position in CLDX in Q4 2023 and held it in 3 quarters. The position peaked at $4.41M in Q4 2023. 184 funds tracked by Wall St. Rank hold CLDX as of Q3 2025.

  • Exome Asset Management reported no remaining Celldex Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Exome Asset Management sold 73,000 Celldex Therapeutics shares in Q3 2025, an estimated $1.49M.
  • Exome Asset Management first reported a position in Celldex Therapeutics in Q4 2023 and held it in 3 quarters.
  • Exome Asset Management's Celldex Therapeutics position peaked at $4.41M in Q4 2023.
  • 184 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2025.

Based on Exome Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.